Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35587859/
doi: 10.1007/s11916-022-01051-9. Online ahead of print. 1 Geisinger Health Systems, Neurology, 1000 E. Mountain Boulevard, Wilkes-Barre, PA, 18711, USA. [email protected]. 2 Ayer Neurosciences Institute, Hartford HealthCare Medical Group, University of...
Conclusion/Relevance: This review highlights safety concerns of commonly used migraine prophylactic agents and offers suggestions on how to mitigate those risks.
-
Dr Hamid3yrInteresting read that aid in decision-making when choosing safe and effective options for preventive migraine medications.
Recognizing vestibular migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35543531/
Vestibular migraine is a recently defined disorder that is underrecognized by clinicians across specialties. Acute attacks cause symptoms of migraine headaches as well as vestibular symptoms such as dizziness or...
Relevance: Vestibular migraine is a recently defined disorder that is underrecognized by clinicians across specialties. Acute attacks cause symptoms of migraine headaches as well as vestibular symptoms such as dizziness or vertigo. Further research is needed to determine the pathophysiology of vestibular migraine. No consensus treatment...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is such a difficult condition to diagnose and treat.
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01426-8
Background Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety...
Conclusions: By adopting this 'one brain, one life, one approach' strategy in cooperation with partner societies, international organisations, and policymakers, a significant number of neurological disorders may be prevented while enhancing the overall well-being of individuals by maintaining brain health through the life course.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrI find this study really intriguing.
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35538414/
doi: 10.1186/s10194-022-01426-8. 1 Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. 2...
Conclusion: In general, erenumab is well tolerated up to a treatment interval of 12 months and reported AEs rarely lead to discontinuation of therapy. A higher dosage does not increase the patient reported AEs. Furthermore, no habituation of AEs is observed. Nevertheless, females and patients with aura seem to be more prone to have AEs.
Autonomic Function Tests, Heart Rate Variability, and Electrophysiological Evaluation in Patients With a Primary Episodic Headache: An Observational Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35512198/
doi: 10.1097/WNP.0000000000000943. Online ahead of print. 1 Departments of Neurology. 2 Physiology, and. 3 Community Medicine, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India; and. 4 Department of...
Conclusions: Autonomic functional abnormality, both sympathetic and parasympathetic, does exist in patients with a primary episodic headache.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis can be good to know if we want to help predict migraine.